Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.34
- Piotroski Score 3.00
- Grade Buy
- Symbol (LAB)
- Company Standard BioTools Inc.
- Price $2.16
- Changes Percentage (-0.92%)
- Change -$0.02
- Day Low $2.12
- Day High $2.21
- Year High $3.04
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.25
- High Stock Price Target $3.25
- Low Stock Price Target $3.25
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.00
- Trailing P/E Ratio -2.32
- Forward P/E Ratio -2.32
- P/E Growth -2.32
- Net Income $-74,656,000
Income Statement
Quarterly
Annual
Latest News of LAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Can Alabama keep its composure in tough road trip to LSU? 3 keys and a prediction
Alabama's initial College Football Playoff ranking has little impact on players and coaches as they were unaware of it. The focus is on the upcoming game against LSU, crucial for Playoff chances. Alab...
By The New York Times | 11 hours ago -
Labor's plan to re-impose ankle bracelet and curfew regime 'very likely' to face legal challenge, advocates say
The Albanese government faces legal challenges over proposals to remove non-citizens, including reintroducing ankle bracelets and curfews. Critics argue the measures violate fundamental rights, prompt...
By The Guardian | 13 hours ago -
LSU may have live tiger on sideline vs Alabama: reports
A highly anticipated SEC matchup between LSU and Alabama will feature a live tiger on the field for the first time in years. Louisiana officials, including Gov. Landry, played a role in bringing back ...
By Fox News | 18 hours ago
